These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34410978)

  • 1. Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma.
    Yoshino M; Ishihara H; Ishiyama Y; Tachibana H; Toki D; Yamashita K; Kobayashi H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Ishida H; Kondo T; Tanabe K
    In Vivo; 2021; 35(5):2855-2862. PubMed ID: 34410978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
    Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albumin-to-alkaline phosphatase ratio: A novel prognostic index for patients with driver mutation-negative advanced non-small cell lung cancer.
    Liu X; Li Y; Zhao Q; Jiang H; Ni J; Cai H
    Clin Respir J; 2021 May; 15(5):540-549. PubMed ID: 33565707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Med Oncol; 2019 Mar; 36(4):35. PubMed ID: 30879157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.
    Fukuda S; Saito K; Yasuda Y; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Kageyama Y; Fujii Y
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
    Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
    Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
    Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low albumin-to-alkaline phosphatase ratio is associated with inferior prognosis in patients with head and neck cancer underwent concurrent chemoradiation: A propensity score-matched analysis.
    Kim D; Ki Y; Kim W; Park D; Joo J; Jeon H; Nam J
    J Cancer Res Ther; 2023; 19(5):1340-1344. PubMed ID: 37787305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: which is better?
    Halit Aktepe O; Sinem Ardic F; Yuce D; Can Guven D; Guner G; Cagri Yildirim H; Kilickap S; Turker A; Kertmen N; Akin S; Aksoy S; Dizdar O; Yalcin S; Erman M
    J BUON; 2021; 26(5):2067-2073. PubMed ID: 34761618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
    Urol Oncol; 2020 May; 38(5):526-532. PubMed ID: 31864934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of serum albumin-to-alkaline phosphatase ratio in cervical cancer patients treated with definitive chemoradiotherapy.
    Onal C; Gultekin M; Yavas G; Oymak E; Yuce Sari S; Guler OC; Yigit E; Yildiz F
    J Obstet Gynaecol; 2022 Aug; 42(6):2426-2432. PubMed ID: 35653776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive role of γ-glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma.
    Ishiyama Y; Kondo T; Tachibana H; Ishihara H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Tanabe K
    Int J Clin Oncol; 2021 Mar; 26(3):552-561. PubMed ID: 33135126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory Prognostic Index in Metastatic Renal Carcinoma Treated with Nivolumab.
    Ekinci F; Erdogan AP; Yildirim S; Bulut G; Yilmaz C; Barutca S
    J Coll Physicians Surg Pak; 2022 Oct; 32(10):1288-1294. PubMed ID: 36205273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Factor in Patients Undergoing Nephrectomy for Non-Metastatic Renal Cell Carcinoma: Propensity Score Matching Analysis.
    Won I; Shim SR; Kim SI; Kim SJ; Cho DS
    Clin Genitourin Cancer; 2022 Jun; 20(3):e253-e262. PubMed ID: 35241381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.
    Bilen MA; Dutcher GMA; Liu Y; Ravindranathan D; Kissick HT; Carthon BC; Kucuk O; Harris WB; Master VA
    Clin Genitourin Cancer; 2018 Jun; 16(3):e563-e575. PubMed ID: 29402706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma.
    Ishihara H; Kondo T; Nakamura K; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Takagi T
    Jpn J Clin Oncol; 2021 Dec; 51(12):1751-1756. PubMed ID: 34492101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of Albumin-to-Alkaline Phosphatase Ratio in upper tract urothelial carcinoma.
    Tan P; Xie N; Ai J; Xu H; Xu H; Liu L; Yang L; Wei Q
    Sci Rep; 2018 Aug; 8(1):12311. PubMed ID: 30120312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.
    Ishihara H; Nemoto Y; Nakamura K; Ikeda T; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Takagi T; Ishida H; Kondo T; Tanabe K
    Target Oncol; 2021 Jul; 16(4):493-502. PubMed ID: 34173936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.